Overview

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Status:
NOT_YET_RECRUITING

Trial end date:
2032-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.

Phase:

PHASE3

Details

Lead Sponsor:

Takara Bio Inc.

Treatments:

Cyclophosphamide
fludarabine